SecBot SecBot
6-K ·Filed Jul 17, 2026

EVAX

Evaxion A/S
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001171843-26-004747
Notable filing: 6-K
Actionable Insight ▲ Bullish

The ESMO presentation in October is the next major catalyst. Traders should watch for abstract release and any pre-ESMO data leaks. The stand-alone therapy data is particularly important as it could de-risk the asset from combination dependency and open a larger addressable market.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.08
T+0 close · Jul 17, 2026 · via day close
Latest settled
−2.44%
T+60 · $3.00
Vs SPY
−7.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 17 $3.08entry
  2. T+1 · 4mo ago −4.39%α −4.23% · $2.94
  3. T+5 · 4mo ago −0.81%α −0.13% · $3.05
  4. T+20 · 3mo ago +8.62%α +4.17% · $3.34
  5. T+60 · 5w ago −2.44%α −7.12% · $3.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced it will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress in October 2026. The data from a phase 2 trial extension will show EVX-01's effect as a stand-alone therapy in advanced melanoma patients, building on previously reported two-year results showing a 75% objective response rate and durable responses. The presentation is a key catalyst for the stock, as positive data could support partnership discussions and late-stage development plans for this lead asset.

Key Facts

  • Evaxion will present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 (October 23-27, 2026) in Madrid.
  • The data comes from a one-year extension of the phase 2 trial where patients received EVX-01 as stand-alone therapy (without anti-PD-1 combination).
  • Previously reported two-year data showed a 75% Objective Response Rate (ORR) with 12 of 16 patients responding, including 4 complete responses, and 92% of patients still responding at two years with no relapses.
  • EVX-01 induced an immune response in all patients, with 86% of targeted neoantigens generating potent T-cell responses.
  • The global market for melanoma treatments is estimated to grow to $7.4 billion by 2029.

Financial Impact

No financial figures provided; the event is a clinical data presentation at a major medical congress, which could materially impact partnership and valuation prospects for the lead asset EVX-01.

Risk Factors

  • The phase 2 trial has only 16 patients, small sample size limits statistical significance and replicability.
  • The company is pre-revenue and needs additional capital, as noted in forward-looking statement risk factors.
  • Data is not yet released; the presentation is three months away, leaving room for negative pre-event drift or disappointing results.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-004747
Document: f6k_071726.htm0001171843-26-004747
Document: 0001171843-26-004747-index-headers.html0001171843-26-004747
Document: 0001171843-26-004747-index.html0001171843-26-004747
Document: 0001171843-26-004747.txt0001171843-26-004747

Track record

50 reports on EVAX

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 17, 2026